Clinical Trial Update: Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of Azeliragon for metastatic pancreatic cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Azeliragon (Azeliragon)

Snippet

Sponsor: Cantex Pharmaceuticals | Conditions: Metastatic Pancreatic Cancer | Phase 1, Phase 2 | Status: RECRUITING